Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir

11 November 2019
Laryngeal cancer can cause irreversible damage to the vocal cords, resulting in loss of voice. This report describes a stage III glottic cancer patient treated with Rigvir therapy, showing good response to treatment and with laryngeal functions still preserved.
Read more: https://journals.lww.com/md-journal/Fulltext/2019/11080/Treatment_of_a_stage_III_rima_glottidis_patient.56.aspx

Contacts for Media Inquiries

Rigvir Group
Address: Atlasa street 7C, Riga, Latvia, LV-1026
Phone: +371 67 716 132
E-mail: pr@rigvir.com